Novel Therapeutic Approaches in the Treatment of Multiple Myeloma

Last Modified: January 13, 2005

Share article


Conference Dates: Friday, March 4, 2005
Conference Location: Turner Building, Johns Hopkins University

Sponsoring Group: Multiple Myeloma Research Foundation

Conference Web Page URL: www.hopkinscme.net/etrakwebapp/meetingdetail.aspx?meetingcode=05-511393

Topics Covered: Focus on discussing the novel therapies, standard treatment approaches, and controversies in the management of multiple myeloma. Future therapeutic approaches based on ongoing pre-clinical work will also be discussed.

Conference Objectives: Identify the diagnostic approaches and prognostic indicators in multiple myeloma; Describe the role and appropriate use of novel treatments for multiple myeloma throughout the disease progression and Discuss the latest advances in stem cell transplantation, treatments for bone disease, and supportive care management

Who Should Attend: Internists, hematologists, medical oncologists, radiation oncologists, and oncology nurses

Conference Agenda:

Welcome and Introduction
Ivan Borrello, MD

Targeting Myeloma Stem Cells
Carol Ann Huff, MD

Prognostic Indicators and Initial Therapy
Mohamad A. Hussein, MD

Advances in Bone Disease and Supportive Care
G. David Roodman, MD, PhD

The Role of Stem Cell Transplantation and Immune Therapy in Multiple Myeloma
Ivan Borrello, MD

Novel Therapies for Relapsed/Refractory Disease
Nikhil Munshi, MD

Registration Information: Visit: www.hopkinscme.net/etrakwebapp/meetingdetail.aspx?meetingcode=05-511393

Conference Fees: $75 doctors/$50 fellows/nurses/allied health professionals

Continuing Education: Yes

Miscellany: There is also a patient program - for more information visit www.multiplemyeloma.org


News
ASH: Novel Drug Beneficial in Multiple Myeloma

Jul 28, 2014 - In patients with relapsed or resistant multiple myeloma who have received up to three prior therapies excluding the first-generation proteasome inhibitor bortezomib, treatment with the second-generation proteasome inhibitor carfilzomib is associated a high response rate and a low incidence of side effects, according to research presented at the annual meeting of the American Society of Hematology, held from Dec. 5 to 8 in New Orleans.



Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.




OncoLink OncoPilot

Facing a new cancer diagnosis or changing the course of your current treatment? Let our cancer nurses help you through!

Learn More